WALTHAM, Mass., Apr 14, 2010 (BUSINESS WIRE) --Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will host its eighth annual European Users Conference (EUC) April 21 - 22 at the Corinthia Hotel in Budapest, Hungary. The conference will offer a full day of industry, product and customer-led sessions.

Company Chairman and CEO, Bob Weiler will commence the plenary session with a welcome keynote address. Lord Robert Winston, Professor of Science and Society and Emeritus Professor of Fertility Studies at Imperial College, will deliver the industry keynote. During his presentation, Lord Winston will discuss the industry's many recent innovations and advancements and review what might lie ahead thanks to the continued adoption of technology.

More than 15 customer-driven sessions will cover a variety of topics and include presentations by Cancer Research UK, Dana-Farber Cancer Institute, ICON Clinical Research, INC Research, Novartis Pharma AG, Quintiles, Servier Pharmaceutical Group, Theravance, UCB and the U.K. Medicines and Healthcare Products Regulatory Agency.

"Like other sectors in healthcare, the pharmaceutical industry is in the midst of a highly transformative period," said Weiler. "Technological shiftsand increased adoptions are impacting everything from drug therapy development and discovery methods to innovative R&D partnerships - and we remain committed to delivering the premier tools and services our customers have come to expect. We applaud their continued dedication to adopting the technologies, practices and standards that will help ensure product efficacy and drug safety worldwide."

To view the full agenda and to register, please click here.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

SOURCE: Phase Forward

Phase Forward
Maria Sumner, +44 1628 640743
maria.sumner@phaseforward.com
or
CHEN PR, Inc.
Juli Greenwood, 781-672-3137
jgreenwood@chenpr.com